PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
21.78
+0.52 (2.45%)
Nov 21, 2024, 3:11 PM EST - Market closed

Company Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.

The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.

In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development.

The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PureTech Health plc
PureTech Health logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 90
CEO Bharatt Chowrira

Contact Details

Address:
6 Tide Street, Suite 400
Boston, Massachusetts 02210
United States
Phone 617 482 2333
Website puretechhealth.com

Stock Details

Ticker Symbol PRTC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001782999
CUSIP Number 746237106
ISIN Number US7462371060
SIC Code 2834

Key Executives

Name Position
Dr. Bharatt M. Chowrira J.D., Ph.D. Chief Executive Officer and Executive Director
Daphne Zohar Founder, Senior Advisor and Board Observer
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder and Non-Executive Director
Dr. Eric Elenko Ph.D. Co-Founder and President
Dr. David R. Elmaleh Ph.D. Co-Founder and Senior Advisor
Lauren A. White M.B.A. Chief Financial Officer
Eric Green M.B.A. Chief Operating Officer
Allison Mead Talbot Head of Communications and Investor Relations
Charles Sherwood III, J.D., Ph.D. General Counsel and Company Secretary
Spencer Ball Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 21, 2024 6-K Report of foreign issuer
Sep 27, 2024 6-K Report of foreign issuer
Aug 28, 2024 6-K Report of foreign issuer
Aug 28, 2024 6-K Report of foreign issuer
Aug 22, 2024 6-K Report of foreign issuer
Jul 8, 2024 4 Statement of changes in beneficial ownership of securities
Jun 24, 2024 6-K Report of foreign issuer
Jun 24, 2024 SC TO-I/A Filing